583 related articles for article (PubMed ID: 18061862)
21. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
Grenader T; Peretz T; Lifchitz M; Shavit L
Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Brunsvold AN; Wung SF; Merkle CJ
J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
[TBL] [Abstract][Full Text] [Related]
24. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
[TBL] [Abstract][Full Text] [Related]
26. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
27. [Familial history of ovarian carcinoma: policy].
de Hullu JA; Kets CM; Massuger LF; Ligtenberg ML; van Ham MA; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2011; 155():A2392. PubMed ID: 21262027
[TBL] [Abstract][Full Text] [Related]
28. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
29. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
31. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
32. Perspectives in the clinical management of BRCA mutations carriers.
Savarese A; Cognetti F
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
[TBL] [Abstract][Full Text] [Related]
33. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
34. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
35. Familial ovarian cancer.
Volm T
Curr Womens Health Rep; 2002 Feb; 2(1):34-8. PubMed ID: 12112981
[TBL] [Abstract][Full Text] [Related]
36. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
37. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
38. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Weber BL
Oncogene; 2006 Sep; 25(43):5825-31. PubMed ID: 16998496
[TBL] [Abstract][Full Text] [Related]
39. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
[TBL] [Abstract][Full Text] [Related]
40. The pros and cons of genetic testing for breast and ovarian cancer risk.
Frank TS; Braverman AM
Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
